Discovery of 2-(3,4-dialkoxyphenyl)-2-(substituted pyridazin-3-yl)acetonitriles as phosphodiesterase 4 inhibitors with anti-neuroinflammation potential based on three-dimensional quantitative structure-activity relationship study.
Acetonitriles
/ chemistry
Animals
Anti-Inflammatory Agents
/ chemistry
Binding Sites
Catalytic Domain
Cell Line
Cell Survival
/ drug effects
Cyclic Nucleotide Phosphodiesterases, Type 4
/ chemistry
Drug Design
Lipopolysaccharides
/ pharmacology
Mice
Microglia
/ cytology
Molecular Docking Simulation
Phosphodiesterase 4 Inhibitors
/ chemistry
Quantitative Structure-Activity Relationship
3D-QSAR
PDE4 inhibitors
anti-neuroinflammation
molecular docking
Journal
Chemical biology & drug design
ISSN: 1747-0285
Titre abrégé: Chem Biol Drug Des
Pays: England
ID NLM: 101262549
Informations de publication
Date de publication:
04 2019
04 2019
Historique:
received:
09
09
2018
revised:
10
10
2018
accepted:
27
10
2018
pubmed:
28
12
2018
medline:
16
1
2020
entrez:
28
12
2018
Statut:
ppublish
Résumé
Phosphodiesterase 4 (PDE4) inhibitors with potential activities for CNS disorders provide a new therapeutic strategy for depression. To discover PDE4 inhibitors with anti-neuroinflammation activities, reliable three-dimensional quantitative structure-activity relationship (3D-QSAR) models on our previous reported catecholic PDE4 inhibitors was built with a statistically significant cross-validated coefficient (q
Substances chimiques
Acetonitriles
0
Anti-Inflammatory Agents
0
Lipopolysaccharides
0
Phosphodiesterase 4 Inhibitors
0
Cyclic Nucleotide Phosphodiesterases, Type 4
EC 3.1.4.17
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
484-502Informations de copyright
© 2018 John Wiley & Sons A/S.